DEF 14A: RadNet, Inc. Announces Details for 2024 Annual Stockholders Meeting

Sentiment:

Proxy Statement 26 April 2024 4:05 PM

RadNet, Inc. has scheduled its 2024 Annual Meeting of Stockholders for June 12, 2024, to address director elections, auditor ratification, executive compensation, and other business matters.

Summary

RadNet, Inc. will hold its 2024 Annual Meeting of Stockholders on June 12, 2024, at its Los Angeles headquarters.
Stockholders will vote on the election of seven director nominees, ratification of Ernst & Young LLP as the independent accounting firm, and an advisory vote on executive compensation.
The Board of Directors has fixed April 17, 2024, as the record date for determining stockholders eligible to vote.
Proxy materials were first sent to stockholders on April 26, 2024.
The company had 73,895,688 shares of common stock issued and outstanding as of the record date.
In 2023, RadNet's revenue was $1.62 billion, an increase of 13.1% over 2022, and income from operations increased by 112.7% to $98.7 million.

Sentiment

Score: 7

Explanation: The document presents a balanced view of RadNet's operations, highlighting both positive financial results and ongoing efforts to improve corporate governance and employee development. The sentiment is moderately positive due to the company's growth and commitment to stakeholder engagement.

Positives

The company encourages stockholders to utilize online access to proxy materials to reduce environmental impact and costs.
RadNet has a diverse workforce, with approximately 81% female and 54% from under-represented groups as of December 31, 2023.
The company offers various internal education and development programs for employees, including leadership development, management training, and technical scholarships.
RadNet provides competitive compensation and benefits, including medical, dental, vision, 401(k), and tuition reimbursement.
The Board of Directors values open dialogue with shareholders and has implemented changes based on shareholder recommendations.
The company has adopted a Policy on Recovery of Erroneously Awarded Compensation or Clawback Policy that is intended to deter both financial/accounting irregularities with respect to RadNet’s financial statements and also misconduct by senior executives.

Risks

Healthcare imaging is dependent on technologically advanced equipment that uses significant energy, posing environmental challenges.
The company faces risks related to cyber security, human capital management, revenue cycle management, and regulatory compliance.
The company's success depends on attracting, retaining, and developing talent.
The company's compensation programs must not encourage short-term risk-taking at the expense of long-term results.
The company's operations are subject to various legal and regulatory requirements, including compliance with the Code of Financial Ethics.

Future Outlook

The company took a number of steps to position itself for future growth, including completion of a secondary public offering raising net proceeds of $245.8 million and continuing its investment in AI technologies and product development.

Management Comments

Our Board believes that diversity brings forward different perspectives and improves decision-making and governance.
Our Board values an open dialogue with shareholders, believing that regular communication is a critical part of the Company's long-term success.

Industry Context

The document provides insight into the corporate governance, executive compensation, and financial performance of a company in the healthcare imaging industry, reflecting trends in healthcare management, technology adoption, and financial performance improvement initiatives.

Comparison to Industry Standards

The document references a peer group of companies including Acadia Healthcare Company, Inc., AdaptHealth Corp, Addus HomeCare Corporation, Apria, Inc., Aveanna Healthcare Holdings Inc., Cano Health, Inc., Fulgent Genetics, Inc., Hanger, Inc., InnovAge Holding Corp., LHC Group, Inc., ModivCare Inc., Pediatrix Medical Group, Inc., Surgery Partners, Inc., and The Ensign Group, Inc.
These companies are used to benchmark executive compensation and assess competitiveness within the healthcare facility and services industry.
The document also mentions Siemens Healthcare North America, IMRIS, Deerfield Imaging, Inc., RealmIDX, Inc., and Fresenius Medical Care AG & Co KGaA, providing context for A. Gregory Sorensen's experience and industry connections.

Related Party Transactions

Howard G. Berger, M.D., is our President and Chief Executive Officer, a Chairman of our Board of Directors, and also owns, indirectly, 99% of the equity interests in Beverly Radiology Medical Group III (BRMG).
On January 1, 2022 we entered into a lease agreement with HFB Heirs Trust II, the holder of approximately 7.2% of our outstanding common stock, with respect to a residential unit located in New York, New York.

Stakeholder Impact

Shareholders: The document provides information relevant to voting decisions and insights into the company's performance and governance.
Employees: The document highlights the company's commitment to diversity, inclusion, and employee development.
Customers: The document emphasizes the company's focus on providing high-quality imaging services and improving patient care.
Suppliers: The document does not directly address the impact on suppliers.
Creditors: The document provides information about the company's financial performance, which is relevant to creditors.

Next Steps

Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
The company will publish the final voting results in a Current Report on Form 8-K filed with the SEC within four business days of the Annual Meeting.
The Board of Directors and Compensation Committee will consider the outcome of the advisory vote on executive compensation when evaluating future compensation arrangements.

Key Dates

Date	Description
1980	Dr. Berger co-founded RadNet.
1987	Dr. Berger has served as President and Chief Executive Officer of RadNet and its predecessor entities since 1987.
1992	Dr. Berger has served as President, Chief Executive Officer and Chairman of the Board since 1992.
1994-01-01	Management Consulting Agreement between Dr. Berger and BRMG.
1996	Norman R. Hames has served as an executive officer of RadNet since 1996.
2004-07	Mark D. Stolper has served as our Executive Vice President and Chief Financial Officer since July 2004.
2004	David L. Swartz has been Chair of our Audit Committee since 2004.
2005-03	Lawrence L. Levitt has been a member of our Audit Committee since March 2005.
2006	Stephen M. Forthuber has served as an executive officer of RadNet since our acquisition of Radiologix, Inc. in 2006.
2007	Lawrence L. Levitt has served as Chair of our Compensation Committee since 2007.
2010	Mital Patel began his career at RadNet in 2010.
2011	David L. Swartz was appointed as Lead Independent Director in 2011.
2016	Mital Patel has served as our Executive Vice President of Financial Planning and Analysis since 2016.
2017-03	Mark D. Stolper has been a member of the board of directors of Surgalign Holdings, Inc. (NASDAQ: SRGA) since March 2017.
2020-03	David J. Katz has served as our Executive Vice President and Chief Legal Officer since March 2020.
2020-06-01	Dr. Sorensen entered into an employment agreement with RMI.
2021-04	David J. Katz has served as our Corporate Secretary since April 2021.
2021	Ranjan Jayanathan currently serves as our Executive Vice President and Chief Information Officer.
2021	Michael Murdock has served as our Executive Vice President, Mergers and Acquisitions since 2021.
2022-01-01	We entered into a lease agreement with HFB Heirs Trust II.
2022-01-26	Ms. Wilson and RMI were parties to an Amended and Restated Severance Agreement, dated January 26, 2022.
2022-02-24	Ms. Gordon and RadNet Management, Inc., a Delaware corporation and wholly owned subsidiary of the Company, (RMI) are parties to an Amended and Restated Severance Agreement, dated February 24, 2022.
2022-06	Over 95% of the stockholder votes (excluding abstained and broker non-votes) were cast FOR the stockholder advisory vote regarding our Named Executive Officers compensation.
2022-09-01	RMI entered into new executive employment agreements with our Named Executive Officers other than Dr. Berger.
2023-01-03	The Company granted Ms. Gordon 8,772 shares of Company common stock.
2023-01-03	The Company granted Dr. Sorensen 31,579 shares of Company common stock.
2023-01-03	The Compensation Committee determined to provide the Named Executive Officers with the cash bonuses which were paid in January 2023.
2023-04-20	Dr. Berger's Agreement with RMI was executed on April 20, 2023.
2023-06-02	Mr. Hames exercised a stock option, with a $6.07 per share exercise price, and acquired 39,127 shares.
2023-06-02	Mr. Hames exercised another stock option, with a $6.30 per share exercise price, and acquired 19,179 shares.
2023-06-07	Each of the non-employee directors received a restricted stock award of 4,066 shares of common stock under our Equity Incentive Plan.
2023-06-07	Our Equity Incentive Plan was most recently approved by our stockholders at our annual stockholders meeting on June 7, 2023.
2023-06	Approximately 88% of the stockholder votes (excluding abstained and broker non-votes) were cast FOR the stockholder advisory vote regarding our Named Executive Officers compensation.
2023-08-08	Dr. Sorensen was appointed as our Chief Science Officer and as a director in August 2023.
2023-11-08	The Board adopted the Policy on Recovery of Erroneously Awarded Compensation.
2023-11	Pearl Meyer provided the Compensation Committee with a compensation benchmarking report on the Company’s Peer Group along with a recommended new Peer Group for fiscal year 2024.
2024-01-01	The management agreement with BRMG automatically renewed for a 10-year period on January 1, 2024.
2024-01-01	The Agreements were each amended as of January 1, 2024 solely to reflect the adjustments to base salary.
2024-01-09	The Compensation Committee determined to provide the Named Executive Officers with the cash bonuses which were paid in January 2024.
2024-02-13	According to a Schedule 13G/A filed with the SEC on February 13, 2024, The Vanguard Group maintains shared voting power over 110,970 shares of our common stock, sole dispositive power over 4,088,529 shares of our common stock and shared dispositive power over 166,188 shares of our common stock.
2024-03-01	Based on 2023 financial data provided by Company management showing that actual AEBITDA was $237,324,127, the Compensation Committee determined that a 110.4% performance level of AEBITDA performance was attained for 2023 and therefore that 100% of the PSOs became performance-based vested and 200% of the PSUs became performance-based vested.
2024-03-31	The following table presents information concerning the beneficial ownership of the shares of our common stock as of March 31, 2024.
2024-04-17	Our Board of Directors fixed April 17, 2024 as the record date for determining stockholders entitled to notice of, and to vote at, the Annual Meeting.
2024-04-26	On or about April 26, 2024, we are mailing a Notice of Internet Availability of Proxy Materials to our stockholders.
2024-06-12	RadNet, Inc. will hold its 2024 Annual Meeting of Stockholders (the Annual Meeting) on Wednesday, June 12, 2024.
2025-02-12	To be timely for the 2025 Annual Meeting of Stockholders, a stockholders notice must be delivered to or mailed and received by our Corporate Secretary at our principal executive offices between February 12, 2025 and March 14, 2025.
2025-03-14	The deadline for providing notice to the Company under Rule 14a-19, the SECs universal proxy rule, of a shareholders intent to solicit proxies in support of nominees submitted under the Companys advance notice bylaws for our 2025 Annual Meeting of Stockholders is March 14, 2025.
2025	Each of the nominees is a current director and all have consented to serving as a nominee, being named in this Proxy Statement, and serving on the Board if elected. Each director elected at the Annual Meeting will be elected to serve a one-year term.
2029	We currently expect that the next advisory vote on the frequency of the say-on-pay votes will occur at the 2029 annual meeting of stockholders.
2033-04-26	Unless terminated earlier, the Equity Incentive Plan will terminate on April 26, 2033.

Keywords

RadNet, Annual Meeting, Stockholders, Directors, Executive Compensation, Proxy Statement, Corporate Governance, Ernst & Young, Audit Committee, Compensation Committee

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.